ATIS

• 

  Attis Industries Executes Purchase Agreement to Acquire Custom Cable Services, Inc.

  12:41 PM | September 10, 2018

  Attis Infrastructure Transaction to Consolidate 5G Infrastructure Companies MILTON, GA, Sept. 10, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company  emphasizing renewable fuels, bio-based plastics, healthcare and building a communications infrastructure, today announced it has executed a purchase agreement to acquire Custom Cable Services, Inc. (“CCS”).  The agreement is an all stock deal valued at $4.6 million.  The transaction commences the formation of a new subsidiary,

  Read more
• 

  Attis Industries Continues to Improve Balance Sheet and Stockholders Equity

  11:58 AM | September 4, 2018

  Goldman Sachs Converts Senior Secured Position into Equity MILTON, GA , Sept. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced it has closed on a new series of Senior Secured Convertible Notes (the “Notes”) with four institutional investors totaling $5,439,000. The proceeds from the new Notes have been used to eliminate $8.8 million of senior secured credit principal while increasing stockholder’s equity by an

  Read more
• 

  Attis Completes Strategic Investment in Noveda Technologies

  5:13 PM | June 8, 2018

  MILTON, GA, June 06, 2018 (GLOBE NEWSWIRE) — Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced the completion of a strategic investment in Noveda Technologies, Inc., a provider of patented web-based, real-time energy and water management solutions. The transaction was completed as part of the Company’s recent acquisition of an 80% stake in FLUX Carbon LLC (“JVCo”), and includes a license to use Noveda’s technologies. Noveda is leading the integration of emerging

  Read more
• 

  Propanc Receives $1.2 Million to Fast Track Animal Safety Studies, GMP Manufacturing and Preclinical Development for Lead Product, PRP

  2:53 PM | March 21, 2016

  Upcoming MHRA Meeting Set to Define Preclinical and Early Stage Clinical Development Pathways PR Newswire MELBOURNE, Australia, March 21, 2016 MELBOURNE, Australia, March 21, 2016 /PRNewswire/ — Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company received $1.2 million from an institutional investor in order to fast track its

  Read more

• 3/3 (IMUC.OB) ImmunoCellular Therapeutics Receives Notice of Allowance for New Antibody Patent

  1:00 AM | March 3, 2010

  “We continue to be excited about working with the Roche Group in the development of this product.”

  Read more